XTL BIOPHARMACEUTICALS LTD. Research and Development Expense
XTL BIOPHARMACEUTICALS LTD. (XTLB) reported Research and Development Expense of $98.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2025-04-30
- XTL BIOPHARMACEUTICALS LTD. research and development expense for the quarter ending 2022-06-30 was $15.00K, a 150.00% increase year-over-year.
- XTL BIOPHARMACEUTICALS LTD. research and development expense for the quarter ending 2021-06-30 was $6.00K, a 45.45% decline year-over-year.
- XTL BIOPHARMACEUTICALS LTD. research and development expense for the quarter ending 2020-06-30 was $11.00K.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 12 month |
|---|---|---|---|
| 2024-12-31 | $98.00K 20-F · filed 2025-04-30 | ||
| 2023-12-31 | $31.00K 20-F · filed 2025-04-30 | ||
| 2022-12-31 | $30.00K 20-F · filed 2025-04-30 | ||
| 2022-06-30 | $15.00K 6-K · filed 2022-08-24 | $21.00K 6-K · filed 2022-08-24 | |
| 2021-12-31 | $30.00K 20-F · filed 2023-03-22 | ||
| 2021-06-30 | $6.00K 6-K · filed 2022-08-24 | $18.00K 6-K · filed 2022-08-24 | |
| 2020-12-31 | $38.00K 20-F · filed 2023-03-22 | ||
| 2020-06-30 | $11.00K 6-K · filed 2021-08-24 | $14.00K 6-K · filed 2021-08-24 | |
| 2019-12-31 | $35.00K 20-F · filed 2022-03-30 | ||
| 2018-12-31 | $38.00K 20-F/A · filed 2021-05-19 | ||
| 2017-12-31 | $43.00K 20-F · filed 2020-03-12 | ||
| 2016-12-31 | $443.00K 20-F · filed 2019-03-11 | ||
| 2015-12-31 | $578.00K 20-F · filed 2018-03-15 |